A new expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: ‘bridging the gap between laboratory data and patient related outcomes’ has just been published in the Expert Review of Hematology journal.
Professor Baba Inusa, scientific coordinator of the ARISE project participated in this work that aims to examine the evidence supporting the laboratory and clinical benefits of voxelotor in Sickle Cell Disease.
Until recently, the treatment of Sickle Cell Disease for a long time has been limited to hydroxycarbamide alone. Voxelotor, a first-in-class haemoglobin modulator that increases haemoglobin-oxygen affinity and reduces red blood cells polymerization, is approved for the treatment of hemolytic anemia in patients with Sickle Cell Disease.
Particularly, authors recommend offering and optimizing hydroxycarbamide therapy and consider voxelotor in situations with severe anemia and related sequelae affecting the brain or kidney.
Read the review here!
